EXOZYMES (NASDAQ: EXOZ) CCO receives 8,887-share stock grant

Rhea-AI Filing Summary

Perriman Damien Alan reported acquisition or exercise transactions in this Form 4 filing.

EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman received a grant of 8,887 shares of common stock on 2026-04-01. The shares were awarded as a compensation-related grant at a reported price of $8.44 per share, rather than through an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Perriman Damien Alan

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	8,887	$8.44	$75K

Holdings After Transaction: COMMON STOCK — 0 shares (Direct)

Footnotes (1)

Key Figures

Shares granted: 8,887 shares Grant price per share: $8.44 per share Transactions acquiring shares: 1 transaction

3 metrics

Shares granted 8,887 shares Common stock grant on April 1, 2026

Grant price per share $8.44 per share Reference price for common stock grant

Transactions acquiring shares 1 transaction AcquireCount from transaction summary

Key Terms

Grant, award, or other acquisition, COMMON STOCK, Chief Commercial Officer

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

COMMON STOCK financial

"security_title: "COMMON STOCK""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Chief Commercial Officer financial

"officer_title: "Chief Commercial Officer""

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perriman Damien Alan

(Last) (First) (Middle)

C/O 750 ROYAL OAKS DRIVE,

SUITE 106

(Street)

MONROVIA CALIFORNIA 91016

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXOZYMES INC. [ EXOZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	04/01/2026	04/01/2026	A		8,887	A	$8.44	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Damien Alan Perriman	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did EXOZ (EXOZYMES INC.) report on this Form 4?

EXOZYMES INC. reported that Chief Commercial Officer Damien Alan Perriman received 8,887 shares of common stock as a grant on April 1, 2026. The award was recorded at a price of $8.44 per share as compensation rather than a market trade.

Was the EXOZ Form 4 transaction a stock purchase or a grant?

The Form 4 for EXOZ shows a stock grant, not a market purchase. The transaction code "A" is described as a grant, award, or other acquisition, indicating compensation-related issuance of 8,887 common shares at a reported $8.44 per share.

Who is the insider involved in the latest EXOZ Form 4 filing?

The insider is Damien Alan Perriman, Chief Commercial Officer of EXOZYMES INC. The filing shows he acquired 8,887 shares of common stock via a grant, categorized as a grant, award, or other acquisition under transaction code A on April 1, 2026.

What type of security is involved in the EXOZ insider grant?

The insider transaction for EXOZ involves common stock. Damien Alan Perriman received 8,887 shares of EXOZYMES INC. common stock through a compensation-related grant, with the award recorded at a reference price of $8.44 per share in the Form 4.

Does the EXOZ Form 4 indicate an open-market buy or sell of shares?

No, the EXOZ Form 4 does not show an open-market buy or sell. It records a grant of 8,887 common shares to Chief Commercial Officer Damien Alan Perriman, using transaction code A for a grant, award, or other acquisition, not a market trade.